
Kevin Larimore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4188237/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria. Clinical and Translational Science, 2021, 14, 1894-1905.	3.1	8
2	Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses. Molecular Genetics and Metabolism, 2021, 134, 235-242.	1.1	4
3	Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Molecular Genetics and Metabolism, 2020, 130, 239-246.	1.1	21
4	Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity. Journal of Immunological Methods, 2019, 468, 20-28.	1.4	9
5	Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Molecular Genetics and Metabolism, 2018, 124, 27-38.	1.1	123
6	Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine, 2018, 37, 366-373.	6.1	58
7	Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. Orphanet Journal of Rare Diseases, 2018, 13, 108.	2.7	25
8	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria. Molecular Genetics and Metabolism, 2018, 125,	1.1	21

217-227.